All In Biotech

Drug Trial Radar · NCT04598880

Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate / Magnesium Citrate for High Quality Colon Cleansing

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,180

Actual

Start

Nov 6, 2020

Primary completion

Apr 1, 2024

Study completion Apr 1, 2024

Sponsor

Lead sponsor
Parc de Salut MarAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: Colorectal cancer is the most frequent neoplasm and the second cause of cancer death in Spain. Colon cleansing is critical for visualization of lesions at colonoscopy. High-quality cleansing allows for correct detection and resection of all lesions and may contribute to adequate risk stratification and follow-up interval. Low-volume laxatives improve tolerance of the colonoscopy preparation without reducing its effectiveness. Currently, the most widely used low-volume laxatives are one liter of Polyethylene glycol + ascorbate (PEG1A) and sodium picosulfate + magnesium citrate (PSCM). The evidence on the comparison of laxatives to achieve a high-quality colonic cleansing is very scarce. Hypothesis: Polyethylene glycol 1 liter with ascorbate is superior to sodium picosulfate and magnesium citrate in high-quality colon cleansing. Objective: Overall objective: To compare the global high-quality cleansing frequency between the two laxatives using the Harefield Scale (HS). The primary objective is to demonstrate non-inferiority in global high-quality cleansing of PEG1A compared to PSCM. If non-inferiority is demonstrated, superiority of PEG1A will be analyzed. Specific objectives: * Frequency of global high-quality cleansing using the Boston Bowel Preparation Scale (BBPS). * Frequency of adequate-quality cleansing using the HS and BBPS scales. * Tolerance and adverse effects of both laxatives. * Detection of lesions, total adenomas, advanced adenomas, total serrated lesions, advanced serrated lesions and colorectal cancer. * Detection of neoplastic lesions in the different colon segments (proximal, transverse, descending, sigmoid and rectum). * Association between detected lesions and the quality of the preparation, according to the HS and BBPS scales. Methods: Phase 4, multi-centric, randomized, single-blind (endoscopist), parallel study with two treatment arms: PEG1A (Pleinvue®) and PSCM (Citrafleet®).

Conditions

  • Colonic Diseases

Interventions

  • Polyethylene glycol + ascorbateDrug

    Pleinvue® is administered orally in 2 doses (3 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose is administered at 9 pm on the day before intervention (sachet 1: MACROGOL 3350 100 g + SODIUM SULFATE ANHYDROUS 9 g + SODIUM CHLORIDE 2 g + POTASSIUM CHLORIDE 1 g). Second dose is administered 5 hours before intervention and it is composed by 2 sachets (sachet A: MACROGOL 3350 40 g + SODIUM CHLORIDE 3,2 g + POTASSIUM CHLORIDE 1,2 g; sachet B: SODIUM ASCORBATE 48,11 g + ASCORBIC ACID 7,54 g).

  • Sodium picosulfate + magnesium citrateDrug

    Citrafleet® is administered orally in 2 doses (2 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose (sachet 1) is administered at 9 pm on the day before intervention. Second dose (sachet 2) is administered 5 hours before intervention. Sachets 1 and 2 have the same composition: SODIUM PICOSULFATE 10 mg + MAGNESIUM OXIDE 3,5 g + CITRIC ACID 10,97 g.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. High quality of entire colon cleansing according to the HSTime frame: At the time of colonoscopy

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Organización Sanitaria Integrada Araba

    Alava, Spain

  • Hospital de Poniente

    Almería, Spain

  • Hospital Germans Trias i Pujol

    Badalona, Spain

  • Hospital del Mar

    Barcelona, Spain

  • Hospital Virgen de las Nieves

    Granada, Spain

  • Clínica Universidad de Navarra

    Madrid, Spain

  • Hospital de la Princesa

    Madrid, Spain

  • Hospital Gregorio Marañón

    Madrid, Spain

  • Hospital La Paz

    Madrid, Spain

  • Hospital Ramón y Cajal

    Madrid, Spain

  • Hospital Quirón

    Málaga, Spain

  • Hospital Costa del Sol

    Marbella, Spain

  • Hospital Santa Bárbara

    Soria, Spain

  • Hospital de Viladecans

    Viladecans, Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.